908 Devices Inc (MASS) - Net Assets
Based on the latest financial reports, 908 Devices Inc (MASS) has net assets worth $134.17 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($186.69 Million) and total liabilities ($52.52 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of 908 Devices Inc to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $134.17 Million |
| % of Total Assets | 71.87% |
| Annual Growth Rate | N/A |
| 5-Year Change | -33.04% |
| 10-Year Change | N/A |
| Growth Volatility | 30.73 |
908 Devices Inc - Net Assets Trend (2018–2025)
This chart illustrates how 908 Devices Inc's net assets have evolved over time, based on quarterly financial data. See defensive interval ratio of 908 Devices Inc to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for 908 Devices Inc (2018–2025)
The table below shows the annual net assets of 908 Devices Inc from 2018 to 2025. For live valuation and market cap data, see 908 Devices Inc market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $143.70 Million | +25.40% |
| 2024-12-31 | $114.59 Million | -30.76% |
| 2023-12-31 | $165.49 Million | -13.17% |
| 2022-12-31 | $190.60 Million | -11.19% |
| 2021-12-31 | $214.60 Million | +54.35% |
| 2020-12-31 | $139.04 Million | +320.11% |
| 2019-12-31 | $-63.17 Million | -25.89% |
| 2018-12-31 | $-50.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to 908 Devices Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 17104000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $36.00K | 0.03% |
| Other Comprehensive Income | $54.00K | 0.04% |
| Other Components | $366.93 Million | 255.34% |
| Total Equity | $143.70 Million | 100.00% |
908 Devices Inc Competitors by Market Cap
The table below lists competitors of 908 Devices Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Summarecon Agung Tbk
JK:SMRA
|
$299.87 Million |
|
Palladyne AI Corp
NASDAQ:PDYN
|
$299.89 Million |
|
M1 Kliniken AG
XETRA:M12
|
$300.08 Million |
|
Australian Clinical Labs Ltd
AU:ACL
|
$300.11 Million |
|
Amplitude Surgical SAS
PA:AMPLI
|
$299.85 Million |
|
Guangdong Jialong Food Co Ltd
SHE:002495
|
$299.84 Million |
|
Colonial Coal International Corp
V:CAD
|
$299.82 Million |
|
Propel Funeral Partners Ltd
AU:PFP
|
$299.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in 908 Devices Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 114,592,000 to 143,699,000, a change of 29,107,000 (25.4%).
- Net loss of 36,639,000 reduced equity.
- New share issuances of 864,000 increased equity.
- Other comprehensive income decreased equity by 1,092,000.
- Other factors increased equity by 65,974,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-36.64 Million | -25.5% |
| Share Issuances | $864.00K | +0.6% |
| Other Comprehensive Income | $-1.09 Million | -0.76% |
| Other Changes | $65.97 Million | +45.91% |
| Total Change | $- | 25.40% |
Book Value vs Market Value Analysis
This analysis compares 908 Devices Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.32x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | $-6.18 | $8.58 | x |
| 2019-12-31 | $-8.39 | $8.58 | x |
| 2020-12-31 | $25.35 | $8.58 | x |
| 2021-12-31 | $7.68 | $8.58 | x |
| 2022-12-31 | $6.05 | $8.58 | x |
| 2023-12-31 | $5.13 | $8.58 | x |
| 2024-12-31 | $3.36 | $8.58 | x |
| 2025-12-31 | $3.69 | $8.58 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently 908 Devices Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -25.50%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.20%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.32x
- Recent ROE (-25.50%) is below the historical average (-18.34%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 0.00% | -34.17% | 0.79x | 0.00x | $-2.52 Million |
| 2019 | 0.00% | -74.41% | 0.48x | 0.00x | $-7.06 Million |
| 2020 | -9.22% | -47.66% | 0.15x | 1.29x | $-26.72 Million |
| 2021 | -10.33% | -52.53% | 0.16x | 1.22x | $-43.63 Million |
| 2022 | -16.65% | -67.75% | 0.19x | 1.27x | $-50.80 Million |
| 2023 | -21.99% | -72.47% | 0.25x | 1.23x | $-52.95 Million |
| 2024 | -63.01% | -121.09% | 0.37x | 1.39x | $-83.67 Million |
| 2025 | -25.50% | -65.20% | 0.30x | 1.32x | $-51.01 Million |
Industry Comparison
This section compares 908 Devices Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| 908 Devices Inc (MASS) | $134.17 Million | 0.00% | 0.39x | $299.86 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About 908 Devices Inc
908 Devices Inc. provides purpose-built handheld mass spectrometry and fourier transform infrared (FTIR) devices for use in vital health and safety applications. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; XplorIR, a handheld device that uses FTIR spe… Read more